A novel red grape cells complex: Health effects and bioavailability of natural resveratrol

International Journal of Food Sciences and Nutrition

Volumn 65, Issue 7, 2014, Pages 848-855

  Azachi, Malkit ^a   Yatuv, Rivka ^a   Katz, Amnon ^a   Hagay, Yochi ^a   Danon, Abraham ^b  

^a Fruitura Bioscience   (Israel)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Piceid; Polyphenols; Red grapes; Resveratrol

Indexed keywords

VITACEAE;

CARRAGEENAN; INDOMETACIN; LOW DENSITY LIPOPROTEIN; RESVERATROL; STILBENE DERIVATIVE;

ADULT; ANIMAL; BIOAVAILABILITY; CHEMICALLY INDUCED; CHEMISTRY; CLASSIFICATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; CYTOLOGY; EDEMA; HUMAN; INFLAMMATION; MALE; METABOLISM; OXIDATION REDUCTION REACTION; RANDOMIZED CONTROLLED TRIAL; RAT; SPRAGUE DAWLEY RAT; VITIS;

ADULT; ANIMALS; BIOLOGICAL AVAILABILITY; CARRAGEENAN; CROSS-OVER STUDIES; EDEMA; HUMANS; INDOMETHACIN; INFLAMMATION; LIPOPROTEINS, LDL; MALE; OXIDATION-REDUCTION; RATS; RATS, SPRAGUE-DAWLEY; STILBENES; VITIS;

EID: 84911887244     PISSN: 09637486     EISSN: 14653478     Source Type: Journal    
DOI: 10.3109/09637486.2014.917152     Document Type: Article

References (58)

1. Aftab N, Likhitwitayawuid K, Vieira A. 2010. Comparative antioxidant activities and synergism of resveratrol and oxyresveratrol. Nat Prod Res 24:1726-1733.
2. Almeida L, Vaz-da-Silva M, Falcaõ A, Soares E, Costa R, Loureiro AI, Fernandes-Lopes C, et al. 2009. Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. Mol Nutr Food Res 53:S7-S15.
3. Amann R, Schuligoi R. 2000. Inhibition of carrageenan-induced edema by indomethacin or sodium salicylate does not prevent the increase of nerve growth factor in the rat hind paw. Neurosci Lett 278:173-176.
4. Amiot MJ, Romier B, Dao TM, Fanciullino R, Ciccolini J, Burcelin R, Pechere L, et al. 2013. Optimization of trans-Resveratrol bioavailability for human therapy. Biochimie 95:1233-1238.
5. Amri A, Chaumeil JC, Sfar S, Charrueau C. 2012. Administration of resveratrol: what formulation solutions to bioavailability limitations J Control Release 158:182-193.
6. Aviram M. 1983. Plasma lipoprotein separation by discontinuous density gradient ultracentrifugation in hyperlipoproteinemic patients. Biochem Med 30:111-118.
7. Aviram M, Vaya J. 2001. Markers for low-density lipoprotein oxidation. Methods Enzymol 335:244-256.
8. Bazzo KO, Souto AA, Lopes TG, Zanin RF, Gomez MV, Souza AH, Campos MM. 2013. Evidence for the analgesic activity of resveratrol in acute models of nociception in mice. J Nat Prod 76:13-21.
9. Biasutto L, Marotta E, Bradaschia A, Fallica M, Mattarei A, Garbisa S, Zoratti M, Paradisi C. 2009. Soluble polyphenols: synthesis and bioavailability of 3,40,5-tri(alpha-D-glucose-3-O-succinyl) resveratrol. Bioorg Med Chem Lett 19:6721-6724.
10. Boocock DJ, Faust GE, Patel KR, Schinas AM, Brown VA, Ducharme MP, Booth TD, et al. 2007a. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev 16: 1246-1252.
11. Boocock DJ, Patel KR, Faust GE, Normolle DP, Marczylo TH, Crowell JA, Brenner DE, et al. 2007b. Quantitation of trans-resveratrol and detection of its metabolites in human plasma and urine by high performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 848:182-187.
12. Bralley EE, Greenspan P, Hargrove JL, Wicker L, Hartle DK. 2008. Topical anti-inflammatory activity of Polygonum cuspidatum extract in the TPA model of mouse ear inflammation. J Inflamm (Lond) 5:1-7.
13. Brown VA, Patel KR, Viskaduraki M, Crowell JA, Perloff M, Booth TD, Vasilinin G. 2010. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res 70:9003-9011.
14. Burkon A, Somoza V. 2008. Quantification of free and protein-bound trans-resveratrol metabolites and identification of trans-resveratrol-C/O-conjugated diglucuronides-two novel resveratrol metabolites in human plasma. Mol Nutr Food Res 52:549-557.
15. Calamini B, Ratia K, Malkowski MG, Cuendet M, Pezzuto JM, Santarsiero BD, Mesecar AD. 2010. Pleiotropic mechanisms facilitated by resveratrol and its metabolites. Biochem J 429:273-282.
16. Catalgol B, Batirel S, Taga Y, Ozer NK. 2012. Resveratrol: French paradox revisited. Front Pharmacol 3:141. doi: 10.3389/fphar.2012.00141.
17. Cottart CH, Nivet-Antoine V, Beaudeux JL. 2014. Review of recent data on the metabolism, biological effects, and toxicity of resveratrol in humans. Mol Nutr Food Res 58:7-21.
18. Cottart CH, Nivet-Antoine V, Laguillier-Morizot C, Beaudeux JL. 2010. Resveratrol bioavailability and toxicity in humans. Mol Nutr Food Res 54:7-16.
19. Deng JS, Chi CS, Huang SS, Shie PH, Lin TH, Huang GJ. 2011. Antioxidant, analgesic, and anti-inflammatory activities of the ethanolic extracts of Taxillus liquidambaricola. J Ethnopharmacol 137:1161-1171.
20. Falchi M, Bertelli A, Galazzo R, Vigano P, Dib B. 2010. Central antalgic activity of resveratrol. Arch Ital Biol 148:389-396.
21. Fuhrman B, Volkova N, Coleman R, Aviram M. 2005. Grape powder polyphenols attenuate atherosclerosis development in apolipoprotein E deficient (E0) mice and reduce macrophage atherogenicity. J Nutr 135: 722-728.
22. Gentilli M, Mazoit JX, Bouaziz H, Fletcher D, Casper RF, Benhamou D, Savouret JF. 2001. Resveratrol decreases hyperalgesia induced by carrageenan in the rat hind paw. Life Sci 68:1317-1321.
23. Giner-Chavez BI, Van Soest PJ, Robertson JB, Lascano C, Reed JD, Pell AN. 1997. A method for isolating condensed Tannins from Crude plant extracts with Trivalent Ytterbium. J Sci Food Agric 74:359-368.
24. Goldberg DM, Ng E, Karumanchiri A, Diamandis EP, Soleas GJ. 1996. Resveratrol glucosides are important components of commercial wines. Am J Enol Vitic 47:415-420.
25. Goldberg DM, Yan J, Soleas GJ. 2003. Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Clin Biochem 36:79-87.
26. Henry-Vitrac C, Desmouliere A, Girard D, Merillon JM, Krisa S. 2006. Transport, deglycosylation, and metabolism of trans-piceid by small intestinal epithelial cells. Eur J Nutr 45:376-382.
27. Hoshino J, Park EJ, Kondratyuk TP, Marler L, Pezzuto JM, van Breemen RB, Mo S, et al. 2012. Selective synthesis and biological evaluation of sulfate-conjugated resveratrol metabolites. J Med Chem 53:5033-5043.
28. Leibowitz A, Faltin Z, Perl A, Eshdat Y, Hagay Y, Peleg E, Grossman E. 2014. Red grape berry-cultured cells reduce blood pressure in rats with metabolic-like syndrome. Eur J Nutr 53:973-980.
29. Liao CR, Chang YS, Peng WH, Lai SC, Ho YL. 2012. Analgesic and antiinflammatory activities of the methanol extract of Elaeagnus oldhamii Maxim. in Mice. Am J Chin Med 40:581-597.
30. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. 1951. Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
31. Lu DL, Ding DJ, Yan WJ, Li RR, Dai F, Wang Q, Yu SS, et al. 2013. Influence of glucuronidation and reduction modifications of resveratrol on its biological activities. Chem BioChem 14:1094-1104.
32. Manach C, Williamson G, Morand C, Scalbert A, Remesy C. 2005. Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am J Clin Nutr 81:230S-242S.
33. Manna SK, Mukhopadhyay A, Aggarwal BB. 2000. Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-Kappa B, activator protein-1, and apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation. J Immunol 164: 6509-6519.
34. Marier JF, Vachon P, Gritsas A, Zhang J, Moreau JP, Ducharme MP. 2002. Metabolism and disposition of resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model. J Pharmacol Exp Ther 302:369-373.
35. Morris CJ. 2003. Carrageenan-induced paw edema in the rat and mouse. Methods Mol Biol 225:115-121.
36. Mulinacci N, Innocenti M, Santamaria AR, la Marca G, Pasqua G. 2010. High-performance liquid chromatography/electrospray ionization tandem mass spectrometric investigation of stilbenoids in cell cultures of Vitis vinifera L., cv. Malvasia. Rapid Commun Mass Spectr 24: 2065-2073.
37. Nunes T, Almeida L, Rocha JF, Falcaõ A, Fernandes-Lopes C, Loureiro AI, Wright L, et al. 2009. Pharmacokinetics of trans-resveratrol following repeated administration in healthy elderly and young subjects. J Clin Pharmacol 49:1477-1482.
38. Opie LH, Lecour S. 2007. The red wine hypothesis: from concepts to protective signalling molecules. Eur Heart J 28:1683-1693.
39. Ortuno J, Covas MI, Farre M, Pujadas M, Fito M, Khymentes O, Andres-Lacueva C, et al. 2010. Matrix effects on the bioavailability of resveratrol in humans. Food Chem 120:1123-1130.
40. Pandey KB, Rizvi SI. 2009. Plant polyphenols as dietary antioxidants in human health and disease. Oxid Med Cell Longev 2: 270-278.
41. Poulsen MM, Vestergaard PF, Clasen BF, Radko Y, Christensen LP, Stodkilde-Jorgensen H, Moller N, et al. 2013. High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes 62:1186-1195.
42. Rayalam S, Della-Fera MA, Baile CA. 2011. Synergism between resveratrol and other phytochemicals: implications for obesity and osteoporosis. Mol Nutr Food Res 55:1177-1185.
43. Regev-Shoshani G, Shoseyov O, Bilkis I, Kerem Z. 2003. Glycosylation of resveratrol protects it from enzymic oxidation. Biochem J 374: 157-163.
44. Roberts MS, Magnusson BM, Burczynski FJ, Weiss M. 2002. Enterohepatic circulation: physiological, pharmacokinetic and clinical implications. Clin Pharmacokinet 41:751-790.
45. Roldán A, Palacios V, Caro I, Perez L. 2003. Resveratrol content of Palomino fino Grapes: influence of vintage and fungal infection. J Agric Food Chem 51:1464-1468.
46. Rotches-Ribalta M, Andres-Lacueva C, Estruch R, Escribano E, Urpi-Sarda M. 2012. Pharmacokinetics of resveratrol metabolic profile in healthy humans after moderate consumption of red wine and grape extract tablets. Pharmacol Res 66:375-382.
47. Sheu MJ, Chou PY, Cheng HC, Wu CH, Huang GJ, Wang BS, Chen JS, et al. 2009. Analgesic and anti-inflammatory activities of a water extract of Trachelospermum jasminoides (Apocynaceae). J Ethnopharmacol 126:332-338.
48. Soleas GJ, Angelini M, Grass L, Diamandis EP, Goldberg DM. 2001. Absorption of trans-resveratrol in rats. Methods Enzymol 335: 145-154.
49. Teng Z, Yuan C, Zhang F, Huan M, Cao W, Li K, Yang J, et al. 2012. Intestinal absorption and first-pass metabolism of polyphenol compounds in rat and their transport dynamics in Caco-2 cells. PLoS One 7:e29647.
50. Tillu DV, Melemedjian OK, Asiedu MN, Qu N, de Felice M, Dussor G, Price TJ. 2012. Resveratrol engages AMPK to attenuate ERK and mTOR signaling in sensory neurons and inhibits incision-induced acute and chronic pain. Mol Pain 8:5. doi: 10.1186/1744-8069-8-5.
51. Vang O, Ahmad N, Baile CA, Baur JA, Brown K, Csiszar A, Das DK, et al. 2011. What is new for an old molecule Systematic review and recommendations on the use of resveratrol. PLoS One 6:e19881.
52. Versari A, Parpinello GP, Tornielli GB, Ferrarini R, Giulivo C. 2001. Stilbene compounds and stilbene synthase expression during ripening, wilting, and UV treatment in grape cv. corvina. J Agric Food Chem 49: 5531-5536.
53. Walle T. 2011. Bioavailability of resveratrol. Ann N Y Acad Sci 1215: 9-15.
54. Walle T, Hsieh F, DeLegge MH, Oatis Jr JE, Walle UK. 2004. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 32:1377-1382.
55. Wang LX, Heredia A, Song H, Zhang Z, Yu B, Davis C, Redfield R. 2004. Resveratrol glucuronides as the metabolites of resveratrol in humans: characterization, synthesis, and anti-HIV activity. J Pharm Sci 93:2448-2457.
56. Williamson G, Manach C. 2005. Bioavailability and bioefficacy of polyphenols in humans. II. Review of 93 intervention studies. Am J Clin Nutr 81:243S-255S.
57. Winter CA, Risley EA, Nuss GW. 1962. Carrageenin-induced edema in hind paw of the rat as an assay for antiinflammatory drugs. Exp Biol Med 111:544-547.
58. Wong RH, Howe PR, Buckley JD, Coates AM, Kunz I, Berry NM. 2011. Acute resveratrol supplementation improves flow-mediated dilatation in overweight/obese individuals with mildly elevated blood pressure. Nutr Metab Cardiovasc Dis 21:851-856.